Novartis

Activities: Training & Education Manufacturing Drug Delivery Research & Development Pharmaceutical

Trending Articles

  1. PROFINET enables the seamless integration of Watson-Marlow pumps into Kühner single-use bioreactors A PROFINET interface has enabled the seamless integration of Watson-Marlow 630PnN/R and 730PnN/R pumps into the Siemens environment of Adolf Kühner AG’s SB2500-Z orbital...
  2. Richter BioLogics cuts the ribbon on its Bovenau biopharma facility The CDMO has expanded its European presence with a protein and plasmid biomanufacturing facility situated in South Germany
  3. Merck launches single-use reactor designed to accelerate antibody drug conjugate manufacturing First scalable single-use mixer specifically designed for ADC manufacturing. It increases efficiency by 70% compared to stainless steel or glass manufacturing methods and...
  4. Knowledge and adaptability drive successful pharmaceutical outsourcing partnerships Third-party contract manufacturers and packers play an increasingly prominent role in the pharmaceutical sector, helping companies to both navigate the complexities of the...
  5. Advancing targeted protein degraders: leveraging CMC strategies for rapid IND submission and bioavailability solutions In the rapidly evolving pharmaceutical landscape, targeted protein degraders (TPDs) represent a significant leap forward. TPDs offer a novel therapeutic modality with the...

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Research & Development

Novartis' Leqvio demonstrates LDL cholesterol management potential in Phase III trial

The siRNA can significantly reduce the levels of LDL cholesterol in the blood, reducing the risk of ASCVD in patients
Regulatory

Novartis' Fabhalta bags FDA accelerated approval for Berger's disease

Fabhalta, or iptacopan, is a complement inhibitor designed to reduce proteinuria in primary IgA nephropathy, a chronic kidney disease
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Unither Pharmaceuticals acquires Novartis' Brazilian manufacturing facility

Unither has acquired Novartis' Brazilian plant São Paulo, Brazil, in order to enlarge its reach on multidose ophthalmic containers, benefitting from the sterile operations facility
Manufacturing

Novartis completes acquisition of precision medicine developer Chinook

Novartis has announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics
Subscribe now